nodes	percent_of_prediction	percent_of_DWPC	metapath
Conivaptan—Infusion site pain—Capecitabine—esophageal cancer	0.0382	0.0811	CcSEcCtD
Conivaptan—Phlebitis—Carboplatin—esophageal cancer	0.0244	0.0519	CcSEcCtD
Conivaptan—Atrial arrhythmia—Capecitabine—esophageal cancer	0.0226	0.0479	CcSEcCtD
Conivaptan—Arrhythmia supraventricular—Capecitabine—esophageal cancer	0.0162	0.0343	CcSEcCtD
Conivaptan—Atorvastatin—ABCC2—esophageal cancer	0.011	0.337	CrCbGaD
Conivaptan—Infection—Carboplatin—esophageal cancer	0.0103	0.0218	CcSEcCtD
Conivaptan—Hypomagnesaemia—Capecitabine—esophageal cancer	0.00986	0.0209	CcSEcCtD
Conivaptan—Oral candidiasis—Capecitabine—esophageal cancer	0.00986	0.0209	CcSEcCtD
Conivaptan—Pharyngolaryngeal pain—Capecitabine—esophageal cancer	0.00928	0.0197	CcSEcCtD
Conivaptan—Lomitapide—ABCB1—esophageal cancer	0.00927	0.285	CrCbGaD
Conivaptan—Laryngeal pain—Capecitabine—esophageal cancer	0.00919	0.0195	CcSEcCtD
Conivaptan—Pain—Carboplatin—esophageal cancer	0.00884	0.0188	CcSEcCtD
Conivaptan—Tolvaptan—ABCB1—esophageal cancer	0.00826	0.254	CrCbGaD
Conivaptan—Body temperature increased—Carboplatin—esophageal cancer	0.00817	0.0174	CcSEcCtD
Conivaptan—Phlebitis—Cisplatin—esophageal cancer	0.00716	0.0152	CcSEcCtD
Conivaptan—Polyuria—Cisplatin—esophageal cancer	0.00702	0.0149	CcSEcCtD
Conivaptan—Hyponatraemia—Cisplatin—esophageal cancer	0.00619	0.0132	CcSEcCtD
Conivaptan—Candida infection—Capecitabine—esophageal cancer	0.00598	0.0127	CcSEcCtD
Conivaptan—CYP3A4—Fatty Acid Omega Oxidation—ADH1B—esophageal cancer	0.00583	0.0117	CbGpPWpGaD
Conivaptan—Dehydration—Cisplatin—esophageal cancer	0.00574	0.0122	CcSEcCtD
Conivaptan—Urine output increased—Capecitabine—esophageal cancer	0.00566	0.012	CcSEcCtD
Conivaptan—Orthostatic hypotension—Cisplatin—esophageal cancer	0.00563	0.012	CcSEcCtD
Conivaptan—Hypokalaemia—Cisplatin—esophageal cancer	0.00561	0.0119	CcSEcCtD
Conivaptan—Sepsis—Capecitabine—esophageal cancer	0.00544	0.0115	CcSEcCtD
Conivaptan—CYP3A4—Irinotecan Pathway—ABCC2—esophageal cancer	0.00538	0.0108	CbGpPWpGaD
Conivaptan—Phlebitis—Capecitabine—esophageal cancer	0.00528	0.0112	CcSEcCtD
Conivaptan—AVPR1A—G alpha (q) signalling events—GNG7—esophageal cancer	0.00527	0.0106	CbGpPWpGaD
Conivaptan—Polyuria—Capecitabine—esophageal cancer	0.00518	0.011	CcSEcCtD
Conivaptan—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—esophageal cancer	0.00517	0.0104	CbGpPWpGaD
Conivaptan—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—esophageal cancer	0.00493	0.00993	CbGpPWpGaD
Conivaptan—Atrial fibrillation—Capecitabine—esophageal cancer	0.0048	0.0102	CcSEcCtD
Conivaptan—Thirst—Capecitabine—esophageal cancer	0.00478	0.0102	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—ADCYAP1—esophageal cancer	0.00474	0.00953	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—GNG7—esophageal cancer	0.00471	0.00948	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—ADCYAP1—esophageal cancer	0.0047	0.00947	CbGpPWpGaD
Conivaptan—Cardiac failure—Capecitabine—esophageal cancer	0.00466	0.0099	CcSEcCtD
Conivaptan—CYP3A4—Drug Induction of Bile Acid Pathway—ABCC2—esophageal cancer	0.0046	0.00927	CbGpPWpGaD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—CXCL2—esophageal cancer	0.00458	0.00922	CbGpPWpGaD
Conivaptan—Hyponatraemia—Capecitabine—esophageal cancer	0.00457	0.0097	CcSEcCtD
Conivaptan—AVPR2—Peptide ligand-binding receptors—CXCL2—esophageal cancer	0.00455	0.00915	CbGpPWpGaD
Conivaptan—CYP3A4—Codeine and Morphine Metabolism—ABCB1—esophageal cancer	0.00447	0.00899	CbGpPWpGaD
Conivaptan—AVPR1A—G alpha (q) signalling events—ANXA1—esophageal cancer	0.00431	0.00868	CbGpPWpGaD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—ANXA1—esophageal cancer	0.00426	0.00857	CbGpPWpGaD
Conivaptan—Dehydration—Capecitabine—esophageal cancer	0.00423	0.00898	CcSEcCtD
Conivaptan—AVPR2—Peptide ligand-binding receptors—ANXA1—esophageal cancer	0.00423	0.00851	CbGpPWpGaD
Conivaptan—Urine output increased—Methotrexate—esophageal cancer	0.00422	0.00896	CcSEcCtD
Conivaptan—Urinary tract disorder—Cisplatin—esophageal cancer	0.00421	0.00895	CcSEcCtD
Conivaptan—Urethral disorder—Cisplatin—esophageal cancer	0.00418	0.00889	CcSEcCtD
Conivaptan—Orthostatic hypotension—Capecitabine—esophageal cancer	0.00415	0.00882	CcSEcCtD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—SST—esophageal cancer	0.00414	0.00834	CbGpPWpGaD
Conivaptan—Hypokalaemia—Capecitabine—esophageal cancer	0.00414	0.00879	CcSEcCtD
Conivaptan—AVPR2—Peptide ligand-binding receptors—SST—esophageal cancer	0.00411	0.00828	CbGpPWpGaD
Conivaptan—CYP3A4—Fatty Acid Omega Oxidation—ALDH2—esophageal cancer	0.00411	0.00827	CbGpPWpGaD
Conivaptan—AVPR1A—G alpha (q) signalling events—GHRL—esophageal cancer	0.00409	0.00823	CbGpPWpGaD
Conivaptan—Sepsis—Methotrexate—esophageal cancer	0.00405	0.0086	CcSEcCtD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—GHRL—esophageal cancer	0.00404	0.00813	CbGpPWpGaD
Conivaptan—Atorvastatin—ABCB1—esophageal cancer	0.00403	0.124	CrCbGaD
Conivaptan—AVPR2—Peptide ligand-binding receptors—GHRL—esophageal cancer	0.00401	0.00807	CbGpPWpGaD
Conivaptan—Cardiac disorder—Cisplatin—esophageal cancer	0.00396	0.00841	CcSEcCtD
Conivaptan—CYP3A4—Fatty Acid Omega Oxidation—CYP2A6—esophageal cancer	0.00386	0.00778	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—esophageal cancer	0.00386	0.00776	CbGpPWpGaD
Conivaptan—Polyuria—Methotrexate—esophageal cancer	0.00385	0.00819	CcSEcCtD
Conivaptan—Mediastinal disorder—Cisplatin—esophageal cancer	0.00385	0.00817	CcSEcCtD
Conivaptan—Erythema—Cisplatin—esophageal cancer	0.00371	0.00789	CcSEcCtD
Conivaptan—Malnutrition—Cisplatin—esophageal cancer	0.00371	0.00789	CcSEcCtD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—esophageal cancer	0.00366	0.00736	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.00364	0.00733	CbGpPWpGaD
Conivaptan—Hyperglycaemia—Capecitabine—esophageal cancer	0.00354	0.00753	CcSEcCtD
Conivaptan—Pneumonia—Capecitabine—esophageal cancer	0.00352	0.00749	CcSEcCtD
Conivaptan—Infestation NOS—Capecitabine—esophageal cancer	0.0035	0.00744	CcSEcCtD
Conivaptan—Infestation—Capecitabine—esophageal cancer	0.0035	0.00744	CcSEcCtD
Conivaptan—Anaemia—Cisplatin—esophageal cancer	0.00343	0.00729	CcSEcCtD
Conivaptan—AVPR2—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.00342	0.00689	CbGpPWpGaD
Conivaptan—Urinary tract infection—Capecitabine—esophageal cancer	0.00341	0.00724	CcSEcCtD
Conivaptan—Haematuria—Capecitabine—esophageal cancer	0.00334	0.0071	CcSEcCtD
Conivaptan—AVPR2—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.00324	0.00653	CbGpPWpGaD
Conivaptan—CYP3A4—Xenobiotics—CYP2A6—esophageal cancer	0.00323	0.00651	CbGpPWpGaD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00314	0.00667	CcSEcCtD
Conivaptan—CYP3A4—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.00311	0.00626	CbGpPWpGaD
Conivaptan—Urinary tract disorder—Capecitabine—esophageal cancer	0.00311	0.0066	CcSEcCtD
Conivaptan—Oedema peripheral—Capecitabine—esophageal cancer	0.0031	0.00658	CcSEcCtD
Conivaptan—AVPR2—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.0031	0.00623	CbGpPWpGaD
Conivaptan—Urethral disorder—Capecitabine—esophageal cancer	0.00308	0.00655	CcSEcCtD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.00307	0.00618	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.00305	0.00614	CbGpPWpGaD
Conivaptan—Infection—Cisplatin—esophageal cancer	0.00301	0.0064	CcSEcCtD
Conivaptan—Nervous system disorder—Cisplatin—esophageal cancer	0.00297	0.00632	CcSEcCtD
Conivaptan—AVPR2—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.00297	0.00597	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.00297	0.00597	CbGpPWpGaD
Conivaptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.00297	0.00597	CbGpPWpGaD
Conivaptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.00297	0.00597	CbGpPWpGaD
Conivaptan—Skin disorder—Cisplatin—esophageal cancer	0.00294	0.00626	CcSEcCtD
Conivaptan—Cardiac disorder—Capecitabine—esophageal cancer	0.00292	0.0062	CcSEcCtD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.00286	0.00575	CbGpPWpGaD
Conivaptan—Angiopathy—Capecitabine—esophageal cancer	0.00285	0.00606	CcSEcCtD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.00284	0.00571	CbGpPWpGaD
Conivaptan—Mediastinal disorder—Capecitabine—esophageal cancer	0.00283	0.00602	CcSEcCtD
Conivaptan—CYP3A4—Estrogen metabolism—CYP1B1—esophageal cancer	0.00283	0.0057	CbGpPWpGaD
Conivaptan—Hypotension—Cisplatin—esophageal cancer	0.00283	0.00602	CcSEcCtD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.00278	0.00559	CbGpPWpGaD
Conivaptan—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.00278	0.00559	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.00276	0.00555	CbGpPWpGaD
Conivaptan—Mental disorder—Capecitabine—esophageal cancer	0.00276	0.00586	CcSEcCtD
Conivaptan—Malnutrition—Capecitabine—esophageal cancer	0.00274	0.00582	CcSEcCtD
Conivaptan—Erythema—Capecitabine—esophageal cancer	0.00274	0.00582	CcSEcCtD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.00271	0.00545	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.00269	0.00541	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.00268	0.00539	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.00266	0.00535	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—GNG7—esophageal cancer	0.00266	0.00535	CbGpPWpGaD
Conivaptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.00264	0.00532	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—GNG7—esophageal cancer	0.00264	0.00531	CbGpPWpGaD
Conivaptan—Pneumonia—Methotrexate—esophageal cancer	0.00262	0.00557	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00262	0.00556	CcSEcCtD
Conivaptan—Infestation—Methotrexate—esophageal cancer	0.00261	0.00554	CcSEcCtD
Conivaptan—Infestation NOS—Methotrexate—esophageal cancer	0.00261	0.00554	CcSEcCtD
Conivaptan—Pain—Cisplatin—esophageal cancer	0.00259	0.00551	CcSEcCtD
Conivaptan—Anaemia—Capecitabine—esophageal cancer	0.00253	0.00538	CcSEcCtD
Conivaptan—CYP3A4—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00251	0.00504	CbGpPWpGaD
Conivaptan—Feeling abnormal—Cisplatin—esophageal cancer	0.0025	0.00531	CcSEcCtD
Conivaptan—Haematuria—Methotrexate—esophageal cancer	0.00249	0.00528	CcSEcCtD
Conivaptan—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—esophageal cancer	0.00244	0.00492	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—ADCYAP1—esophageal cancer	0.00243	0.00489	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—ADCYAP1—esophageal cancer	0.00241	0.00486	CbGpPWpGaD
Conivaptan—Body temperature increased—Cisplatin—esophageal cancer	0.0024	0.00509	CcSEcCtD
Conivaptan—Hypertension—Capecitabine—esophageal cancer	0.00236	0.00502	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—CXCL2—esophageal cancer	0.00234	0.00471	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—CXCL2—esophageal cancer	0.00232	0.00468	CbGpPWpGaD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00232	0.00492	CcSEcCtD
Conivaptan—Urinary tract disorder—Methotrexate—esophageal cancer	0.00231	0.00491	CcSEcCtD
Conivaptan—Urethral disorder—Methotrexate—esophageal cancer	0.0023	0.00488	CcSEcCtD
Conivaptan—Dry mouth—Capecitabine—esophageal cancer	0.00228	0.00484	CcSEcCtD
Conivaptan—Confusional state—Capecitabine—esophageal cancer	0.00225	0.00479	CcSEcCtD
Conivaptan—AVPR2—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.00225	0.00453	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—GDI2—esophageal cancer	0.00223	0.00449	CbGpPWpGaD
Conivaptan—Infection—Capecitabine—esophageal cancer	0.00222	0.00472	CcSEcCtD
Conivaptan—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.00222	0.00447	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—GDI2—esophageal cancer	0.00221	0.00445	CbGpPWpGaD
Conivaptan—Nervous system disorder—Capecitabine—esophageal cancer	0.00219	0.00466	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—ANXA1—esophageal cancer	0.00218	0.00438	CbGpPWpGaD
Conivaptan—Cardiac disorder—Methotrexate—esophageal cancer	0.00217	0.00462	CcSEcCtD
Conivaptan—Skin disorder—Capecitabine—esophageal cancer	0.00217	0.00461	CcSEcCtD
Conivaptan—AVPR2—GPCR ligand binding—ANXA1—esophageal cancer	0.00216	0.00435	CbGpPWpGaD
Conivaptan—Angiopathy—Methotrexate—esophageal cancer	0.00212	0.00451	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—SST—esophageal cancer	0.00212	0.00426	CbGpPWpGaD
Conivaptan—Mediastinal disorder—Methotrexate—esophageal cancer	0.00211	0.00448	CcSEcCtD
Conivaptan—AVPR2—GPCR ligand binding—SST—esophageal cancer	0.0021	0.00423	CbGpPWpGaD
Conivaptan—Hypotension—Capecitabine—esophageal cancer	0.00209	0.00444	CcSEcCtD
Conivaptan—Diarrhoea—Cisplatin—esophageal cancer	0.00207	0.00441	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—GHRL—esophageal cancer	0.00206	0.00415	CbGpPWpGaD
Conivaptan—Mental disorder—Methotrexate—esophageal cancer	0.00205	0.00436	CcSEcCtD
Conivaptan—AVPR2—GPCR ligand binding—GHRL—esophageal cancer	0.00205	0.00412	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.00204	0.00411	CbGpPWpGaD
Conivaptan—Malnutrition—Methotrexate—esophageal cancer	0.00204	0.00433	CcSEcCtD
Conivaptan—Erythema—Methotrexate—esophageal cancer	0.00204	0.00433	CcSEcCtD
Conivaptan—Insomnia—Capecitabine—esophageal cancer	0.00202	0.00429	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00193	0.0041	CcSEcCtD
Conivaptan—Vomiting—Cisplatin—esophageal cancer	0.00193	0.0041	CcSEcCtD
Conivaptan—Constipation—Capecitabine—esophageal cancer	0.00191	0.00406	CcSEcCtD
Conivaptan—Pain—Capecitabine—esophageal cancer	0.00191	0.00406	CcSEcCtD
Conivaptan—Anaemia—Methotrexate—esophageal cancer	0.00188	0.004	CcSEcCtD
Conivaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.00188	0.00379	CbGpPWpGaD
Conivaptan—CYP3A4—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.00187	0.00377	CbGpPWpGaD
Conivaptan—CYP3A4—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.00186	0.00374	CbGpPWpGaD
Conivaptan—Feeling abnormal—Capecitabine—esophageal cancer	0.00184	0.00391	CcSEcCtD
Conivaptan—Nausea—Cisplatin—esophageal cancer	0.0018	0.00383	CcSEcCtD
Conivaptan—Body temperature increased—Capecitabine—esophageal cancer	0.00177	0.00375	CcSEcCtD
Conivaptan—CYP3A4—Tryptophan metabolism—ALDH2—esophageal cancer	0.00177	0.00355	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—AKAP13—esophageal cancer	0.00173	0.00347	CbGpPWpGaD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00172	0.00366	CcSEcCtD
Conivaptan—AVPR2—GPCR downstream signaling—AKAP13—esophageal cancer	0.00171	0.00345	CbGpPWpGaD
Conivaptan—Confusional state—Methotrexate—esophageal cancer	0.00168	0.00356	CcSEcCtD
Conivaptan—Infection—Methotrexate—esophageal cancer	0.00165	0.00351	CcSEcCtD
Conivaptan—CYP3A4—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.00164	0.00331	CbGpPWpGaD
Conivaptan—Nervous system disorder—Methotrexate—esophageal cancer	0.00163	0.00347	CcSEcCtD
Conivaptan—Skin disorder—Methotrexate—esophageal cancer	0.00162	0.00343	CcSEcCtD
Conivaptan—AVPR1A—Signaling Pathways—KMT2D—esophageal cancer	0.00161	0.00324	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—KMT2D—esophageal cancer	0.0016	0.00322	CbGpPWpGaD
Conivaptan—Pruritus—Capecitabine—esophageal cancer	0.00158	0.00336	CcSEcCtD
Conivaptan—AVPR1A—GPCR downstream signaling—PDE4D—esophageal cancer	0.00158	0.00318	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—AKAP13—esophageal cancer	0.00157	0.00315	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—PDE4D—esophageal cancer	0.00157	0.00315	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—AKAP13—esophageal cancer	0.00156	0.00313	CbGpPWpGaD
Conivaptan—Hypotension—Methotrexate—esophageal cancer	0.00155	0.0033	CcSEcCtD
Conivaptan—Diarrhoea—Capecitabine—esophageal cancer	0.00153	0.00325	CcSEcCtD
Conivaptan—CYP3A4—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.00153	0.00307	CbGpPWpGaD
Conivaptan—Insomnia—Methotrexate—esophageal cancer	0.0015	0.0032	CcSEcCtD
Conivaptan—AVPR1A—GPCR downstream signaling—GNG7—esophageal cancer	0.0015	0.00302	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—GNG7—esophageal cancer	0.00149	0.003	CbGpPWpGaD
Conivaptan—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.00147	0.00296	CbGpPWpGaD
Conivaptan—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00144	0.00305	CcSEcCtD
Conivaptan—AVPR1A—Signaling Pathways—ADCYAP1—esophageal cancer	0.00144	0.00289	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—PDE4D—esophageal cancer	0.00143	0.00288	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—ADCYAP1—esophageal cancer	0.00143	0.00287	CbGpPWpGaD
Conivaptan—Pain—Methotrexate—esophageal cancer	0.00142	0.00302	CcSEcCtD
Conivaptan—AVPR2—Signaling by GPCR—PDE4D—esophageal cancer	0.00142	0.00286	CbGpPWpGaD
Conivaptan—Vomiting—Capecitabine—esophageal cancer	0.00142	0.00302	CcSEcCtD
Conivaptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.0014	0.00282	CbGpPWpGaD
Conivaptan—Headache—Capecitabine—esophageal cancer	0.0014	0.00297	CcSEcCtD
Conivaptan—Feeling abnormal—Methotrexate—esophageal cancer	0.00137	0.00291	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—GNG7—esophageal cancer	0.00136	0.00274	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—GNG7—esophageal cancer	0.00135	0.00272	CbGpPWpGaD
Conivaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.00134	0.0027	CbGpPWpGaD
Conivaptan—CYP3A4—Tryptophan metabolism—CYP1B1—esophageal cancer	0.00134	0.00269	CbGpPWpGaD
Conivaptan—Nausea—Capecitabine—esophageal cancer	0.00133	0.00282	CcSEcCtD
Conivaptan—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.00132	0.00267	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—CXCL2—esophageal cancer	0.00132	0.00266	CbGpPWpGaD
Conivaptan—Body temperature increased—Methotrexate—esophageal cancer	0.00132	0.00279	CcSEcCtD
Conivaptan—AVPR1A—Signaling Pathways—WWOX—esophageal cancer	0.00131	0.00264	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—CXCL2—esophageal cancer	0.00131	0.00264	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—WWOX—esophageal cancer	0.0013	0.00262	CbGpPWpGaD
Conivaptan—CYP3A4—Tryptophan metabolism—CYP19A1—esophageal cancer	0.00126	0.00253	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—FKBP1A—esophageal cancer	0.00125	0.00251	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.00124	0.0025	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—FKBP1A—esophageal cancer	0.00124	0.0025	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—ANXA1—esophageal cancer	0.00123	0.00247	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—WIF1—esophageal cancer	0.00122	0.00246	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—ANXA1—esophageal cancer	0.00122	0.00246	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—WIF1—esophageal cancer	0.00121	0.00244	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—CXCL2—esophageal cancer	0.0012	0.00242	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—SST—esophageal cancer	0.0012	0.00241	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.00119	0.0024	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—CXCL2—esophageal cancer	0.00119	0.0024	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—SST—esophageal cancer	0.00119	0.00239	CbGpPWpGaD
Conivaptan—Pruritus—Methotrexate—esophageal cancer	0.00118	0.0025	CcSEcCtD
Conivaptan—AVPR1A—GPCR downstream signaling—GHRL—esophageal cancer	0.00117	0.00235	CbGpPWpGaD
Conivaptan—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.00116	0.00233	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—GHRL—esophageal cancer	0.00116	0.00233	CbGpPWpGaD
Conivaptan—Diarrhoea—Methotrexate—esophageal cancer	0.00114	0.00242	CcSEcCtD
Conivaptan—AVPR1A—Signaling Pathways—CSNK1A1—esophageal cancer	0.00113	0.00227	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CSNK1A1—esophageal cancer	0.00112	0.00225	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—ANXA1—esophageal cancer	0.00112	0.00225	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—ANXA1—esophageal cancer	0.00111	0.00223	CbGpPWpGaD
Conivaptan—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.00109	0.00219	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—SST—esophageal cancer	0.00109	0.00219	CbGpPWpGaD
Conivaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.00108	0.00218	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—SST—esophageal cancer	0.00108	0.00217	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	0.00107	0.00215	CbGpPWpGaD
Conivaptan—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.00107	0.00215	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—GHRL—esophageal cancer	0.00106	0.00213	CbGpPWpGaD
Conivaptan—Vomiting—Methotrexate—esophageal cancer	0.00106	0.00225	CcSEcCtD
Conivaptan—AVPR1A—Signaling Pathways—PFN1—esophageal cancer	0.00105	0.00212	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—GHRL—esophageal cancer	0.00105	0.00211	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PFN1—esophageal cancer	0.00105	0.00211	CbGpPWpGaD
Conivaptan—Headache—Methotrexate—esophageal cancer	0.00104	0.00221	CcSEcCtD
Conivaptan—AVPR1A—G alpha (q) signalling events—PIK3CA—esophageal cancer	0.00104	0.00209	CbGpPWpGaD
Conivaptan—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.00103	0.00208	CbGpPWpGaD
Conivaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.00102	0.00205	CbGpPWpGaD
Conivaptan—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.001	0.00202	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.000995	0.002	CbGpPWpGaD
Conivaptan—Nausea—Methotrexate—esophageal cancer	0.000988	0.0021	CcSEcCtD
Conivaptan—AVPR1A—Signaling Pathways—ELMO1—esophageal cancer	0.000947	0.00191	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—ELMO1—esophageal cancer	0.00094	0.00189	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.000927	0.00187	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—AKAP13—esophageal cancer	0.000925	0.00186	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—AKAP13—esophageal cancer	0.000919	0.00185	CbGpPWpGaD
Conivaptan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000877	0.00177	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000872	0.00176	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000854	0.00172	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000848	0.00171	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PDE4D—esophageal cancer	0.000846	0.0017	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PDE4D—esophageal cancer	0.00084	0.00169	CbGpPWpGaD
Conivaptan—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000825	0.00166	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.000811	0.00163	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—GNG7—esophageal cancer	0.000805	0.00162	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.0008	0.00161	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—GNG7—esophageal cancer	0.000799	0.00161	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000798	0.00161	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—XIAP—esophageal cancer	0.000754	0.00152	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.000754	0.00152	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—XIAP—esophageal cancer	0.000749	0.00151	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.000744	0.0015	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CTNNA1—esophageal cancer	0.000713	0.00144	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CXCL2—esophageal cancer	0.000709	0.00143	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CTNNA1—esophageal cancer	0.000708	0.00143	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CXCL2—esophageal cancer	0.000704	0.00142	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PSME2—esophageal cancer	0.000663	0.00133	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PSME1—esophageal cancer	0.000663	0.00133	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—ANXA1—esophageal cancer	0.000659	0.00133	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PSME2—esophageal cancer	0.000658	0.00132	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PSME1—esophageal cancer	0.000658	0.00132	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—ANXA1—esophageal cancer	0.000655	0.00132	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—SST—esophageal cancer	0.000641	0.00129	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—SST—esophageal cancer	0.000637	0.00128	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—GHRL—esophageal cancer	0.000625	0.00126	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—NOTCH3—esophageal cancer	0.000625	0.00126	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—NOTCH3—esophageal cancer	0.000621	0.00125	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—GHRL—esophageal cancer	0.000621	0.00125	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—FBXW7—esophageal cancer	0.000615	0.00124	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.000615	0.00124	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—FBXW7—esophageal cancer	0.000611	0.00123	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.000585	0.00118	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.000578	0.00116	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—NOTCH2—esophageal cancer	0.000561	0.00113	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—NOTCH2—esophageal cancer	0.000557	0.00112	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000548	0.0011	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—TGFBR2—esophageal cancer	0.000497	0.001	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—TGFBR2—esophageal cancer	0.000494	0.000994	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—SMAD4—esophageal cancer	0.000471	0.000948	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—SMAD4—esophageal cancer	0.000467	0.000941	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000466	0.000938	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000459	0.000925	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000438	0.000882	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000432	0.000869	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—HIF1A—esophageal cancer	0.000385	0.000775	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—HIF1A—esophageal cancer	0.000382	0.00077	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—KDR—esophageal cancer	0.000368	0.000742	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—KDR—esophageal cancer	0.000366	0.000736	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—NOTCH1—esophageal cancer	0.000347	0.000699	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—NOTCH1—esophageal cancer	0.000345	0.000693	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CREBBP—esophageal cancer	0.000315	0.000633	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CREBBP—esophageal cancer	0.000312	0.000629	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—EGFR—esophageal cancer	0.000309	0.000622	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—EGFR—esophageal cancer	0.000307	0.000618	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000296	0.000595	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000293	0.000591	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—NOS3—esophageal cancer	0.000282	0.000567	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—NOS3—esophageal cancer	0.00028	0.000563	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—PIK3CA—esophageal cancer	0.000268	0.00054	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—PIK3CA—esophageal cancer	0.000266	0.000536	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—ERBB2—esophageal cancer	0.000264	0.00053	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—ERBB2—esophageal cancer	0.000262	0.000527	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—SLC52A3—esophageal cancer	0.000235	0.000474	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—BLVRB—esophageal cancer	0.000235	0.000474	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CCND1—esophageal cancer	0.000233	0.000469	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CCND1—esophageal cancer	0.000231	0.000465	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CDKN1A—esophageal cancer	0.000225	0.000453	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CDKN1A—esophageal cancer	0.000224	0.00045	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—EP300—esophageal cancer	0.000214	0.000431	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—EP300—esophageal cancer	0.000213	0.000428	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CA1—esophageal cancer	0.0002	0.000403	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—SLC10A2—esophageal cancer	0.0002	0.000403	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—MYC—esophageal cancer	0.000187	0.000376	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—MYC—esophageal cancer	0.000185	0.000373	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CA2—esophageal cancer	0.000183	0.000368	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—EGFR—esophageal cancer	0.000183	0.000368	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—EGFR—esophageal cancer	0.000181	0.000365	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PLCE1—esophageal cancer	0.00017	0.000342	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ADH7—esophageal cancer	0.00017	0.000342	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PIK3CA—esophageal cancer	0.000159	0.000319	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PIK3CA—esophageal cancer	0.000157	0.000317	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—TP53—esophageal cancer	0.000153	0.000309	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—TP53—esophageal cancer	0.000152	0.000306	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ADH1B—esophageal cancer	0.000149	0.0003	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—TYMP—esophageal cancer	0.000143	0.000287	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CYP26A1—esophageal cancer	0.000139	0.000279	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ALOX15—esophageal cancer	0.000135	0.000272	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GSTO1—esophageal cancer	0.000129	0.00026	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—TPI1—esophageal cancer	0.000129	0.00026	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ALDOB—esophageal cancer	0.000124	0.000249	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GAPDH—esophageal cancer	0.000119	0.00024	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CRABP1—esophageal cancer	0.000118	0.000237	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GNG7—esophageal cancer	0.000112	0.000226	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ALDH2—esophageal cancer	0.000105	0.000212	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GSTT1—esophageal cancer	0.0001	0.000201	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CYP2A6—esophageal cancer	9.88e-05	0.000199	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ENO1—esophageal cancer	9.37e-05	0.000189	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PTGS1—esophageal cancer	9.37e-05	0.000189	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PSME1—esophageal cancer	9.23e-05	0.000186	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PSME2—esophageal cancer	9.23e-05	0.000186	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CYP1B1—esophageal cancer	7.97e-05	0.00016	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CYP19A1—esophageal cancer	7.49e-05	0.000151	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—HMOX1—esophageal cancer	6.84e-05	0.000138	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ABCB1—esophageal cancer	6.56e-05	0.000132	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CREBBP—esophageal cancer	4.38e-05	8.83e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—NOS3—esophageal cancer	3.93e-05	7.9e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PTGS2—esophageal cancer	3.59e-05	7.23e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—EP300—esophageal cancer	2.99e-05	6.01e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PIK3CA—esophageal cancer	2.21e-05	4.45e-05	CbGpPWpGaD
